Market Cap
$2.2B
BHC
Bausch Health Companies Inc.
$5.80 ▲ +1.31%
Prev close $5.73Market cap$2.2B
12-mo target$7.50 (+29.2%)
26 New Institutional Positions17 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on BHC right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Inst. Holders
50 funds
Inst. Value
$870.1M
Inst. Activity
26 buys / 17 sells
Insider Activity
$0.00 buy / $506.7K sell
Insider Net $
-$506.7K
Social Sentiment
50° Neutral
SEC Reports
1
Press Releases
1
Price chart 30d -14.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 2, 2026 short_volume
Aug 27, 2026 Press Short Volume: BHC — 61.8% short (0.5M / 0.8M)
Short: 521,808 | Exempt: 150 | TRF Vol: 843,919 | Short Ratio: 61.8% | Off-exchange volume (dark poo
Bausch Health announced the recipients of its 2026 Aspire Higher Scholarship Program, awarding six students up to $10,00
Impact 1/10
Aug 19, 2026 Insider
Lenar Aimee J. sold 36,827 shares
President, US Pharma @ $7.03 ($258.9K)
Jul 17, 2026 Insider
Lenar Aimee J. surrendered for taxes 5,260 shares
President, US Pharma @ $4.83 ($25.4K)
Jul 15, 2026 Insider
Lenar Aimee J. surrendered for taxes 23,395 shares
President, US Pharma @ $4.89 ($114.4K)
Jun 30, 2026 Inst.
GENDELL JEFFREY L — ADD
4,037,091 shares ($19.9M)
Jun 30, 2026 Inst.
NORGES BANK — NEW
3,431,117 shares ($16.9M)
May 28, 2026 Event
Siliq
WARNING: SUICIDAL IDEATION AND BEHAVIOR Suicidal ideation and behavior, including completed suicides
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Apr 27, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 0 | 4 | 3 | 1 | 0% | |
| Aug 1, 2026 | 0 | 0 | 4 | 3 | 1 | 0% | |
| Jul 1, 2026 | 0 | 0 | 4 | 3 | 1 | 0% | |
| Jun 1, 2026 | 0 | 0 | 5 | 3 | 1 | 0% | |
| May 1, 2026 | 0 | 0 | 5 | 3 | 1 | 0% | |
| Apr 1, 2026 | 0 | 0 | 5 | 3 | 1 | 0% | |
| Mar 1, 2026 | 0 | 0 | 5 | 3 | 1 | 0% | |
| Feb 1, 2026 | 0 | 0 | 5 | 3 | 1 | 0% |
Price targets
Where 5 covering analysts think BHC trades over the next 12 months.
$7.50 +29.2% upside Strong Buy
Current$5.81 Low$6.50 Median$7.00 High$9.00 5 analysts
$6.50$9.00
Analyst rating Hold· 3.0/5 as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
1 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 2.0/10.Plus 1 press releases.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 2, 2026
short_volume
Short Volume: BHC — 61.8% short (0.5M / 0.8M)
Short: 521,808 | Exempt: 150 | TRF Vol: 843,919 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Sep 1, 2026
other
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
The next generation in skin resurfacing technology is available to Australian health care practitioners beginning September 1, 2026 LAVAL, QC, Sept. 1
Sep 1, 2026
short_volume
Short Volume: BHC — 61.8% short (0.7M / 1.1M)
Short: 654,737 | Exempt: 101 | TRF Vol: 1,058,924 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Sep 1, 2026
ftd
FTD: BHC — 450,836 shares ($2.9M) failed to deliver
Settlement: 20260901, Price: $6.37, FTD Value: $2,871,825.32, BAUSCH HEALTH COMPANIES INC CO
Aug 31, 2026
short_volume
Short Volume: BHC — 66.6% short (0.6M / 1.0M)
Short: 640,510 | Exempt: 1 | TRF Vol: 962,000 | Short Ratio: 66.6% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.22 | $1.01–$1.33 | 4.5% | +2.0% | 1↑ 2↓ | $2.7B | 6 |
| Next Q | $1.30 | $1.17–$1.43 | 18.1% | +2.1% | 0↑ 3↓ | $2.8B | 6 |
| Current FY | $4.47 | $4.03–$4.76 | 19.2% | +0.0% | 2↑ 1↓ | $10.9B | 6 |
| Next FY | $4.19 | $3.44–$4.80 | -6.1% | +0.0% | 1↑ 2↓ | $10.9B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.216 | — |
| 7d ago | $1.192 | +0.024 |
| 30d ago | $1.192 | +0.024 |
| 60d ago | $1.168 | +0.048 |
| 90d ago | $1.281 | -0.065 |
Institutional ownership
Which big funds own BHC (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $870.1M total value (174,459,163 shares) as of 2026-Q2. Top holders: PAULSON, ROYAL, HEALTHCARE. Net buying activity: 26 institutions added/increased vs 17 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| PAULSON & CO. INC. | 73,255,869 | $361.2M | 41.5% | — |
| ROYAL BANK OF CANADA | 10,832,582 | $53.4M | 6.1% | — |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 8,000,000 | $39.4M | 4.5% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,465,468 | $36.8M | 4.2% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,803,485 | $33.2M | 3.8% | DOUBLED +145.3% |
| GOLDMAN SACHS GROUP INC | 6,225,131 | $30.7M | 3.5% | — |
| Hudson Bay Capital Management LP | 5,000,000 | $24.6M | 2.8% | — |
| ING GROEP NV | 5,000,000 | $24.6M | 2.8% | — |
| GENDELL JEFFREY L | 4,037,091 | $19.9M | 2.3% | ADD +35.9% |
| NORGES BANK | 3,431,117 | $16.9M | 1.9% | NEW |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GENDELL JEFFREY L | ADD | 2,969,840 | 4,037,091 | +35.9% | $19.9M |
| NORGES BANK | NEW | — | 3,431,117 | — | $16.9M |
| D. E. Shaw & Co., Inc. | DOUBLED | 621,755 | 2,689,942 | +332.6% | $13.3M |
| Point72 Asset Management, L.P. | ADD | 1,350,262 | 2,235,821 | +65.6% | $11.0M |
| Qube Research & Technologies Ltd | ADD | 1,110,726 | 1,681,918 | +51.4% | $8.3M |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | ADD | 1,113,755 | 1,494,205 | +34.2% | $7.4M |
| Man Group plc | DOUBLED | 527,655 | 1,451,781 | +175.1% | $7.2M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 436,755 | 1,095,104 | +150.7% | $5.4M |
| JPMORGAN CHASE & CO | ADD | 453,807 | 880,839 | +94.1% | $4.3M |
| Bridgewater Associates, LP | ADD | 670,366 | 866,285 | +29.2% | $4.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 41 transactions. Net -$506.7K — $0.00 bought, $506.7K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Lenar Aimee J. | President, US Pharma | SELL | 36,827 | $7.03 | $258.9K |
| Jul 17, 2026 | Lenar Aimee J. | President, US Pharma | TAX W/H | 5,260 | $4.83 | $25.4K |
| Jul 15, 2026 | Lenar Aimee J. | President, US Pharma | TAX W/H | 23,395 | $4.89 | $114.4K |
| Jul 14, 2026 | LEE STEVEN HYOSIG | SVP, Controller & CAO | TAX W/H | 3,125 | $4.75 | $14.8K |
| Jun 30, 2026 | WECHSLER AMY B | Director | AWARD | 1,394 | $4.93 | $6.9K |
| Jun 30, 2026 | Paulson John | Director | AWARD | 12,677 | $4.93 | $62.5K |
| Jun 30, 2026 | LEUNG SANDRA | Director | AWARD | 6,845 | $4.93 | $33.7K |
| May 22, 2026 | Garcia Christian A | Director | AWARD | 45,871 | — | — |
| May 22, 2026 | GOETTLER MICHAEL | Director | AWARD | 45,871 | — | — |
| May 22, 2026 | KAVANAGH SARAH B | Director | AWARD | 45,871 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BHC.
Shares short
8,627,598
Settlement Sep 15, 2026
Change vs prior
+5.0%
Semi-monthly cycle
Days to cover
3.1
At avg daily volume
Of shares outstanding
≈2.3%
Estimate — not % of float
All BHC filing & press-release reports (2)
- PRESS-RELEASE reportAug 27, 2026
- DEFA14A reportApr 8, 2026